ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -12.11% | 9.19% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -12.11% | 9.19% | |||
| Cost of Revenue | 114.36% | -1.86% | |||
| Gross Profit | -105.81% | 19.38% | |||
| SG&A Expenses | -15.94% | 19.27% | |||
| Depreciation & Amortization | 7.43% | 1.03% | |||
| Other Operating Expenses | -90.02% | -53.13% | |||
| Total Operating Expenses | -23.03% | 19.39% | |||
| Operating Income | 23.36% | -19.73% | |||
| Income Before Tax | 17.71% | -15.91% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 17.71% | -15.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 17.71% | -15.91% | |||
| EBIT | 23.36% | -19.73% | |||
| EBITDA | 29.68% | -24.46% | |||
| EPS Basic | 20.09% | -14.02% | |||
| Normalized Basic EPS | 20.08% | -13.79% | |||
| EPS Diluted | 16.36% | -16.98% | |||
| Normalized Diluted EPS | 20.08% | -13.79% | |||
| Average Basic Shares Outstanding | 3.07% | 1.69% | |||
| Average Diluted Shares Outstanding | 3.07% | 1.69% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||